The exceptional accuracy in the targeting of CD138 on MM cells can significantly reduce the systemic toxicities associated with conventional chemotherapy and stimulate the patient’s immune system to efficiently recognize and attack malignant cells, potentially leading to long-term positive benefits. Here, SDC1 is linked to Miyoshi myopathy.